Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

SC-8109

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
SC-8109
Clinical data
Other names19-Norspirolactone; 19-Nor-17α-(2-carboxyethyl)testosterone γ-lactone; 3-Oxo-17β-hydroxyestr-4-ene-17-propanoic acid lactone; 17-Hydroxy-3-oxo-19-Nor-17α-pregn-4-ene-21-carboxylic acid γ-lactone
Identifiers
  • (8R,9S,10R,13S,14S,17R)-13-Methylspiro[1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-17,5'-oxolane]-2',3-dione
CAS Number
PubChemCID
ChemSpider
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC21H28O3
Molar mass328.452 g·mol−1
3D model (JSmol)
  • C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]24CCC(=O)O4)CCC5=CC(=O)CC[C@H]35
  • InChI=1S/C21H28O3/c1-20-9-6-16-15-5-3-14(22)12-13(15)2-4-17(16)18(20)7-10-21(20)11-8-19(23)24-21/h12,15-18H,2-11H2,1H3/t15-,16+,17+,18-,20-,21+/m0/s1
  • Key:CXXAIOQMCGJVHT-XUJOMZSTSA-N

SC-8109 is asteroidalantimineralocorticoid of thespirolactone group which was never marketed.[1][2] It is a potentantagonist of themineralocorticoid receptor and is more potent than the related drugSC-5233 (of which SC-8109 is the 19-noranalogue).[1][3] However, SC-8109 was found to have relatively loworalbioavailability andpotency,[1][4] though it nonetheless produced a milddiuretic effect in patients withcongestive heart failure.[2]Spironolactone (SC-9420; Aldactone), another spirolactone, followed and had both good oral bioavailability and potency, and was the first antimineralocorticoid to be marketed.[1][5]

In addition to its antimineralocorticoid activity, SC-8109 shows potentprogestogenic activity, with similar potency relative to that ofprogesterone.[6] Its analogue, SC-5233, possesses similar but less potent progestogenic activity.[6] In addition, SC-5233 has been assessed and found to possess someantiandrogenic activity, antagonizing the effects oftestosterone in animals, and SC-8109 may as well.[7]

Relative affinities (%) of SC-8109 and related steroids[8]
CompoundPRTooltip Progesterone receptorARTooltip Androgen receptorERTooltip Estrogen receptorGRTooltip Glucocorticoid receptorMRTooltip Mineralocorticoid receptorSHBGTooltip Sex hormone-binding globulinCBGTooltip Corticosteroid binding globulin
Progesterone1003–10<1<13–10??
SC-810919125–50<1<115–25??
Values are percentages (%). Referenceligands (100%) wereprogesterone for thePRTooltip progesterone receptor,testosterone for theARTooltip androgen receptor,estradiol for theERTooltip estrogen receptor,DEXATooltip dexamethasone for theGRTooltip glucocorticoid receptor, andaldosterone for theMRTooltip mineralocorticoid receptor.

See also

[edit]

References

[edit]
  1. ^abcdBentley PJ (1980)."The Adrenal Gland".Endocrine Pharmacology: Physiological Basis and Therapeutic Applications. CUP Archive. pp. 160–.ISBN 978-0-521-22673-8.
  2. ^abBuchborn E, Bock KD (14 December 2013).Diuresis and Diuretics / Diurese und Diuretica: An International Symposium Herrenchiemsee, June 17th–20th, 1959 Sponsored by CIBA / Ein Internationales Symposium Herrenchiemsee, 17.–20. Juni 1959 Veranstaltet mit Unterstützung der CIBA. Springer-Verlag. pp. 224, 261.ISBN 978-3-642-49716-2.
  3. ^Ussing HH, Kruhoffer P, Thaysen HJ, Thorn NH (8 March 2013).The Alkali Metal Ions in Biology: I. The Alkali Metal Ions in Isolated Systems and Tissues. II. The Alkali Metal Ions in the Organism. Springer Science & Business Media. pp. 418–.ISBN 978-3-642-49246-4.
  4. ^Brandon ML (1 January 1962).Corticosteroids in medical practice. Thomas.ISBN 9780398002152.{{cite book}}:ISBN / Date incompatibility (help)
  5. ^Cokkinos DV (6 November 2014).Introduction to Translational Cardiovascular Research. Springer. pp. 61–.ISBN 978-3-319-08798-6.
  6. ^abDorfman RI (5 December 2016).Steroidal Activity in Experimental Animals and Man. Elsevier Science. pp. 371–.ISBN 978-1-4832-7299-3.
  7. ^Kagawa CM, Sturtevant FM, Van Arman CG (June 1959). "Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone".The Journal of Pharmacology and Experimental Therapeutics.126 (2):123–130.doi:10.1016/S0022-3565(25)25602-6.PMID 13665517.[SC-5233] (total dose of 5 mg/rat) partially blocked the effects of testosterone propionate on the seminal vesicles and prostate in similar animals.
  8. ^Raynaud JP, Ojasoo T, Bouton MM, Philibert D (1979)."Receptor Binding as a Tool in the Development of New Bioactive Steroids".Drug Design. Medicinal Chemistry: A Series of Monographs. Vol. 11. Academic Press. pp. 169–214.doi:10.1016/B978-0-12-060308-4.50010-X.ISBN 9780120603084.
MRTooltip Mineralocorticoid receptor
Agonists
Antagonists
PRTooltip Progesterone receptor
Agonists
Mixed
(SPRMsTooltip Selective progesterone receptor modulators)
Antagonists
mPRTooltip Membrane progesterone receptor
(PAQRTooltip Progestin and adipoQ receptor)
Agonists
Antagonists

This article about apregnanes is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=SC-8109&oldid=1323778910"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp